Legislative Advocacy
- ASHP Statement to the Senate Committee on Health, Education, Labor, and Pensions: "Managing Pain During the Opioid Crisis"
- ASHP Submits Letter of Support for S. 3519
- Issue Brief: H.R. 6 - SUPPORT for Patients and Communities Act
- ASHP Urges Senate to Pass Opioid Bill Containing Key Provisions
- ASHP Submits Letter to Leaders of the Energy and Commerce Health Subcommittee on Pharmacists Role in Managing the Opioid Crisis
- ASHP Submits Policy Recommendations on Ways to Improve Response to Opioid Epidemic
- ASHP Joins Others in Statement for the Record: “Federal Efforts To Combat The Opioid Crisis: A Status Update On Cara And Other Initiatives”
Regulatory Advocacy
- ASHP and Others Request FDA Use Enforcement Discretion Under the Drug Supply Chain Security Act [PDF]
- ASHP Submits Comments to NIOSH Regarding Additions to the NIOSH Hazardous Drug List 2020
- ASHP comments on FDA Guidance on OTC Transition Approvals
- ASHP Supports EPA in Addressing Hazardous Waste Pharmaceuticals [PDF]
- ASHP Frequently Asked Questions: DEA Proposed Rule on the Disposal of Controlled Substances (DEA-316) [PDF]
- ASHP Letter to FDA: Track and Trace Compliance Questions
- ASHP Comments on Medicare Hospital Discharge Rule
- ASHP Supports FDA Draft Guidance on Single-Use Injectables; Recommends Harmonization with USP and CDC
- ASHP Does not Support FDA’s Draft Guidance on Biologic Product Naming
- ASHP Urges Delay in Enforcement of Track and Trace Requirements [PDF]
- ASHP Does not Support the WHO’s Proposal for Biosimilar Naming Qualifiers [PDF]
- Accurate Tracking of Drugs under DSCSA Will be Challenging Under Current Conditions [PDF]
- ASHP Comments on Proposed Rule on Labeling Changes for Approved Drugs and Biological Products [PDF]
- ASHP Comments on AHRQ Draft Systematic Review: Medication Therapy Management [PDF]
- ASHP Commends HHS on Draft ADE Plan; Offers Additional Insights [PDF]
- ASHP Comments on CMS Proposed Changes to Conditions of Participation for Critical Access Hospitals [PDF]
- ASHP Public Statement to FDA on Communications about REMS
- ASHP Calls on Genentech to Hold Planned Distribution System Change, Meet with Stakeholders [PDF]
- FDA Making Progress on Standardizing REMS, Many Questions Still Remain [PDF]